Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEKARI: Lopinavir/ritonavir Monotherapy in HIV/HCV Co-infection
NCT00866021Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Feb 2008
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: Efficacy of concomitant treatment with lopinavir/r monotherapy and PEG-INF plus RBV for the control of both HIV and HCV infection at 12 months. Started Feb 2008; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00866021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00866021.